ImmuPharma (LON:IMM) Shares Down 19.5% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price traded down 19.5% during trading on Thursday. The company traded as low as GBX 3.21 and last traded at GBX 3.21. Approximately 1,367,494 shares were traded during trading, a decline of 44% from the average session volume of 2,443,213 shares. The stock had previously closed at GBX 3.98.

ImmuPharma Trading Up 2.0%

The firm has a market cap of £20.40 million, a price-to-earnings ratio of -8.84 and a beta of 3.01. The firm’s 50 day simple moving average is GBX 3.80 and its two-hundred day simple moving average is GBX 4.30.

ImmuPharma (LON:IMM) last announced its earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 633.14% and a net margin of 3,519.56%. As a group, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.